Mirati Therapeutics, Inc.

NasdaqGS:MRTX 주식 보고서

시가총액: US$4.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mirati Therapeutics 미래 성장

Future 기준 확인 2/6

Mirati Therapeutics (는) 각각 연간 29.9% 및 42.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 33% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -155.2% 로 예상됩니다.

주요 정보

29.9%

수익 성장률

33.0%

EPS 성장률

Biotechs 수익 성장28.7%
매출 성장률42.2%
향후 자기자본 수익률-155.2%
애널리스트 커버리지

Good

마지막 업데이트20 Dec 2023

최근 미래 성장 업데이트

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09
Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Sep 08

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Aug 31

Mirati gains as Amgen posts new combination data for rival cancer drug

Aug 08

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

수익 및 매출 성장 예측

NasdaqGS:MRTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026495-40833-948
12/31/2025312-556-271-26113
12/31/2024173-670-448-44717
12/31/202362-694-553-55117
9/30/202338-726-596-594N/A
6/30/202327-738-591-588N/A
3/31/202319-737-604-600N/A
12/31/202212-741-575-571N/A
9/30/202212-738-586-580N/A
6/30/202278-645-496-489N/A
3/31/202273-634-449-439N/A
12/31/202172-582-399-389N/A
9/30/202174-483-336-327N/A
6/30/202113-491-365-357N/A
3/31/202113-407-328-323N/A
12/31/202013-358-276-272N/A
9/30/202012-329-241-237N/A
6/30/20202-296-196-193N/A
3/31/20202-259-174-172N/A
12/31/20193-213-149-148N/A
9/30/20196-169-127-127N/A
6/30/20195-142-114-114N/A
3/31/20195-125-97-97N/A
12/31/201813-98-70-70N/A
9/30/20189-88-63-63N/A
6/30/20189-77-58-58N/A
3/31/20189-67-55-54N/A
12/31/2017N/A-70-65-65N/A
9/30/2017N/A-72-67-67N/A
6/30/2017N/A-75N/A-70N/A
3/31/2017N/A-79N/A-69N/A
12/31/2016N/A-83N/A-68N/A
9/30/2016N/A-82N/A-68N/A
6/30/2016N/A-81N/A-65N/A
3/31/2016N/A-75N/A-58N/A
12/31/2015N/A-65N/A-51N/A
9/30/2015N/A-57N/A-43N/A
6/30/2015N/A-46N/A-37N/A
3/31/2015N/A-42N/A-34N/A
12/31/2014N/A-44N/A-33N/A
9/30/2014N/A-45N/A-32N/A
6/30/2014N/A-65N/A-27N/A
3/31/2014N/A-62N/A-31N/A
12/31/2013N/A-53N/A-29N/A
9/30/2013N/A-48N/A-27N/A
6/30/2013N/A-24N/A-26N/A

애널리스트 미래 성장 예측

수입 대 저축률: MRTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MRTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MRTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MRTX 의 수익(연간 42.2% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MRTX 의 수익(연간 42.2% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MRTX (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견